贝特类抗动脉粥样硬化药物肌肉毒性研究进展  

Research Progress of Myotoxicity Caused by Anti-atherosclerotic Fibrates

作　　者：王丽娜[1] 潘家琪[1] 刘爱明[1] 杨菊林[2] 芦超越[1] 陈柳君[1] 

机构地区：[1]宁波大学医学院,浙江宁波315211 [2]宁波天一职业技术学院,浙江宁波315100

出　　处：《中国现代应用药学》2012年第6期490-494,共5页Chinese Journal of Modern Applied Pharmacy

基　　金：浙江省自然科学基金(Y2110016);宁波市自然科学基金(2010A610069;2011A610059)

摘　　要：贝特类药物是临床广泛应用的降脂药,因其显著降低甘油三酯水平,常被用于治疗高甘油三酯血症和混合型高脂血症,从而实现抗动脉粥样硬化和预防心血管事件的目的。大量研究报告表明,临床应用贝特类药物能够导致以横纹肌溶解症为代表的肌肉毒性,严重者甚至死亡。本文对贝特类药物肌肉毒性机制的研究进展作以综述,为指导临床用药和毒性机制研究提供参考。Fibrates are a group of agents commonly prescribed for dyslipidemia to prevent atherosclerosis and cardiovascular events in clinic by their action to lower triglyceride. Their indications include hypertriglyceridemia and mixed hyperlipidemia. However, they have been widely reported to cause myotoxicity, including typical fetal rhabdomyolysis. Here, we comprehensively reviewed research progress of myotoxicity caused by fibrates, to help reduce clinical risk and lay a good basis for mechanism investigation.

关 键 词：贝特类 吉非罗齐 肌肉毒性 横纹肌溶解症 动脉粥样硬化 

分 类 号：R969[医药卫生—药理学]